Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma: A Meta-Analysis

IMPORTANCE: Although the combination of nivolumab plus ipilimumab has unquestionable benefit over nivolumab monotherapy in advanced melanoma, currently no summative analyses have compared the combination with nivolumab monotherapy for advanced cancers other than melanoma. OBJECTIVE: To examine wheth...

Descripción completa

Detalles Bibliográficos
Autores principales: Serritella, Anthony V., Shenoy, Niraj K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472261/
https://www.ncbi.nlm.nih.gov/pubmed/37651124
http://dx.doi.org/10.1001/jamaoncol.2023.3295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472261/
https://www.ncbi.nlm.nih.gov/pubmed/37651124
http://dx.doi.org/10.1001/jamaoncol.2023.3295

Ejemplares similares